89bio Highlights Participation at H.C. Wainwright Investor Conference
89bio to Present at the H.C. Wainwright 8th Annual MASH Investor Conference
89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a prominent clinical-stage biopharmaceutical company, announced their participation in the H.C. Wainwright 8th Annual MASH Investor Conference. The event will take place on a selected date in the upcoming days, featuring a fireside chat and one-on-one investor meetings.
Insights on Innovative Therapies
At the conference, the management team of 89bio will discuss the company's focus on developing and commercializing innovative therapies aimed at treating liver and cardiometabolic diseases. This is a critical area where many existing treatments fall short. Their flagship candidate, pegozafermin, is currently undergoing Phase 3 studies targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
Understanding Pegozafermin
Pegozafermin, an engineered fibroblast growth factor 21 (FGF21) analog, is designed to be a pioneering treatment option in this sector. The proprietary glycoPEGylated technology employed in its development enhances its biological activity, significantly extending its half-life. This innovation places 89bio at the forefront of advancements in therapy for conditions with limited treatment options.
Attendance Details and Webcast
The company will partake in engaging discussions and provide valuable insights to investors at the event. Following the conference, a webcast of their presentation will be available for a limited time for those who wish to revisit the discussions or missed the live event. This opportunity underscores 89bio's commitment to transparency and investor relations.
About 89bio: A Closer Look
89bio is headquartered in San Francisco and is dedicated to advancing therapeutic options for patients suffering from liver and cardiometabolic diseases. By focusing on innovative research and cutting-edge technology, the company aims to improve patient outcomes in these critical areas of health.
Commitment to Patient-Centric Care
The mission of 89bio extends beyond mere drug development; it is about creating real change for those who struggle with these often debilitating conditions. Their ongoing trials are a testament to their dedication to addressing unmet medical needs in the healthcare landscape.
Contact Information
For investor inquiries, you can reach Annie Chang at 89bio, Inc. via email. Additional contact details are available for media representatives who wish to learn more about the company's initiatives.
Frequently Asked Questions
What is 89bio's primary focus?
89bio primarily focuses on developing innovative therapies for liver and cardiometabolic diseases.
When is the H.C. Wainwright Investor Conference?
The conference is scheduled for a date in the near future, where 89bio will participate in discussions and presentations.
What is pegozafermin?
Pegozafermin is 89bio's lead candidate targeting metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
How can I access the webcast of the presentation?
The webcast will be available on the investor section of 89bio’s website for approximately 30 days following the conference.
Who can I contact for investor or media inquiries?
You can contact Annie Chang for investor matters or Sheryl Seapy for media inquiries. Their emails are provided for direct communication.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.